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Background: The aim of this pilot study was to examine the effects of additional resistance training after use of
Botulinum Toxin-A (BoNT-A) on the upper limbs in children with cerebral palsy (CP).
Methods: Ten children with CP (9–17 years) with unilaterally affected upper limbs according to Manual Ability
Classification System II were assigned to two intervention groups. One group received BoNT-A treatment (group B),
the other BoNT-A plus eight weeks resistance training (group BT). Hand and arm use were evaluated by means of
the Melbourne assessment of unilateral upper limb function (Melbourne) and Assisting Hand Assessment (AHA).
Measures of muscle strength, muscle tone, and active range of motion were used to assess neuromuscular body
function. Measurements were performed before and two and five months after intervention start. Change scores
and differences between the groups in such scores were subjected to Mann–Whitney U and Wilcoxon Signed Rank
tests, respectively.
Results: Both groups had very small improvements in AHA and Melbourne two months after BoNT-A injections,
without differences between groups. There were significant, or close to significant, short-term treatment effects in
favour of group BT for muscle strength in injected muscles (elbow flexion strength, p= .08) and non-injected
muscles (elbow extension and supination strength, both p= .05), without concomitant increases in muscle tone.
Active supination range improved in both groups, but more so in group BT (p= .09). There were no differences
between the groups five months after intervention start.
Conclusions: Resistance training strengthens non-injected muscles temporarily and may reduce short-term
strength loss that results from BoNT-A injections without increasing muscle tone. Moreover, additional resistance
training may increase active range of motion to a greater extent than BoNT-A alone. None of the improvements in
neuromuscular impairments further augmented use of the hand and arm. Larger clinical trials are needed to
establish whether resistance training can counteract strength loss caused by BoNT-A, whether the combination of
BoNT-A and resistance training is superior to BoNT-A or resistance training alone in improving active range of
motion, and whether increased task-related training is a more effective approach to improve hand and arm use in
children with CP.
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Cerebral palsy (CP) is the most common cause of phys-
ical disability in childhood, with a prevalence of about
2.1 per 1000 live births [1]. Among these children, be-
tween 50–70% have impaired upper limb function [2-4].
According to the International Classification of Func-
tioning, Disability and Health (ICF) framework [5], the
causes and consequences of impaired upper limb func-
tion can be assessed at the levels of body function, activ-
ity, and participation. Spasticity, muscle weakness and
impaired motor control are primary impairments at the
level of body function for children with hemiplegic or
diplegic CP. The primary impairments may give rise to
secondary musculoskeletal complications such as con-
tractures and deformities, again resulting in limited
range of motion [6]. Activity limitations are presumed to
result from these motor impairments and also from add-
itional disturbances of sensation, perception, cognition,
communication, and behaviour [7]. Spasticity, reduced
muscle strength, and limited active supination range
have been found to be related to hand and arm use [8],
which may lead to difficulties performing several activ-
ities of daily living involving reaching, grasping, and ma-
nipulating objects. Consequently, much of the treatment
offered is targeted towards treating neuromuscular
impairments at the level of body functions, while intend-
ing to improve performance at the level of activity [9].
However, there is a lack of evidence as to what extent
these treatments alter the motor prognosis or make a
clinically significant change in hand and arm use at the
level of activity in ICF [10,11].
Injections of Botulinum Toxin-A (BoNT-A) are often
applied to improve impairments at the level of body
functions, such as reducing spasticity, facilitating move-
ment, and preventing secondary contractures, and ultim-
ately improve hand and arm use in children with spastic
CP [9]. The beneficial effect of BoNT-A injections in
spastic lower limbs on gait has been well documented
[12], but there is insufficient evidence with respect to
improvements in hand and arm use [12,13]. A recent
systematic review concluded that there is moderate evi-
dence that BoNT-A injections alone are not effective in
this respect and need to be combined with therapy to
obtain functional gains [14]. However, the most effective
treatment combinations remain unclear. BoNT-A in
combination with resistance training is one treatment
combination that warrants further investigation [14]. A
few studies have investigated the combined effect of
BoNT-A and intensive therapy with strength training as
part of the intensive therapy [e.g., [15-17]]. However,
these did not describe the procedures or measure the ef-
fect of strength training explicitly, making it difficult to
evaluate whether such training has the potential to en-
hance the outcomes of BoNT-A injections. Previously ithas been argued that only antagonists to spastic muscles
should be strengthened in the BoNT-A effect period,
during which spastic agonists have reduced muscle tone,
in order to improve muscle balance across joints [9,18].
However, spastic muscles in the upper limbs have been
found to show reduced strength during voluntary activa-
tion as well [19,20]. In addition, excessive weakness in
injected spastic muscles is the most common adverse ef-
fect following BoNT-A treatment in the upper limbs
[14]. Consequently, both the spastic muscles and their
antagonists should be strengthened.
The objective of this pilot study was to explore the
effects of additional resistance training of spastic mus-
cles and their antagonists on hand and arm use and
neuromuscular body functions in children with CP after
the use of BoNT-A. Hand and arm use were evaluated
both according to capacity (what the child can do) with
Melbourne assessment of unilateral upper limb function
(Melbourne) [21,22], and according to performance
(what the child spontaneously does) with Assisting Hand
Assessment (AHA) [22,23]. Neuromuscular body func-
tions were evaluated by testing active range of motion,
muscle strength and muscle tone in spastic muscles and
their antagonists in children with CP.
Methods
Participants
Participants were recruited from the outpatient records
of the neuro-orthopaedic team at St. Olav’s Hospital
(Trondheim, Norway). Children with CP were eligible to
participate if they had: a) larger deficits in movement of
one upper extremity in comparison to the other, b) func-
tional use of the hands corresponding to Manual Ability
Classification System (MACS) levels I or II [24], and an
active grasp function in the involved extremity corre-
sponding to category 5 (fair active assist) on the Modi-
fied House Functional Classification System [25], c)
functional limitations when using the involved arm be-
cause of increased muscle tone in the forearm and elbow
flexor muscles and a difference in active and passive
range of motion, and d) were able to follow instructions
and motivated to complete an eight week intensive re-
sistance training program. Exclusion criteria were: a)
treatment with BoNT-A in the upper extremities during
the last six months, b) surgery on the upper extremity in
the last two years prior to participation, and c) on-going
intensive training.
Thirty-one children were assessed and eighteen were
found to be eligible to participate in the study. Eight of
the eighteen refused to participate because they did not
want BoNT-A injections. The remaining ten participants
comprised nine children with hemiplegic and one with
diplegic CP, all with MACS level II. These were matched
in pairs based on age and assigned through tossing a
Table 2 Details of the Botulinum Toxin-A (BoNT-A)
treatment for the participants in groups B and BT
Participant Group B Group BT
Muscle groups injected: Muscle groups injected:
1 Pronator teres Pronator teres
2 Pronator teres, biceps
brachii, brachialis
Pronator teres








5 Pronator teres Pronator teres
Pronator teres 25–50 units BOTOXW (Allergan, Inc.).
Biceps brachii 50–75 units BOTOXW (Allergan, Inc.).
Brachialis 25–50 units BOTOXW (Allergan, Inc.).
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tions (group B, n = 5) or to a group receiving localized
BoNT-A injections and resistance training (group BT,
n = 5). Table 1 shows the demographic data for each of
the groups.
The study was approved by the Regional Committee
for Medical and Health Research Ethics. Written
informed consent was obtained from the participants
and parents before participation.
Data were collected from September 2006 until March
2008. Participants were assessed on three occasions: be-
fore intervention (Baseline) and at two months (Post
2 months) and five months (Post 5 months) after the
BoNT-A treatment, whether or not participating in re-
sistance training. Baseline data from the study have been
reported in a previous publication [8].
Interventions
All the participants were instructed to continue their
usual daily activities during the study period. None of
the participants in group B performed specific training
related to hand function, whereas those in group BT
performed single-joint resistance training without add-
itional functional training.
All participants in groups B and BT received BoNT-A
injections in m. pronator teres. In addition, three partici-
pants in group B and two in group BT received BoNT-A
injections in m. biceps brachii and m. brachialis. Details
of BoNT-A treatment are listed in Table 2. No partici-
pants received injections in spastic muscles in the hand
or fingers because we wanted to avoid potential loss of
grip strength [26] that might influence the possibility to
perform the resistance training. BOTOXW from Allergan
(Irvine, CA) was used (dilution 100 U/1 mL) and dosage
was 25 or 50 U per injection sites, one site in pronator
teres and brachialis, and two sites in biceps brachii. An
experienced physician who was blinded for group assign-
ment decided the dosage and performed the injections
under general anaesthesia. A muscle stimulator was used
in order to optimize accuracy of the injections of prona-
tor teres [27].
The participants in group BT trained three times a
week for eight weeks under supervision of a trainedTable 1 Demographic data for the groups
Group B Group BT
(n= 5) (n = 5)
Mean age (SD) 12 years (3.3 years) 14.8 years (3.0 years)
Male/female (n) 4/1 1/4
CP type, hemiplegic/diplegic(n) 4/1 5/0
Group B = Botulinum Toxin-A injections.
Group BT = Botulinum Toxin-A injections + eight weeks of resistance training.
n = number of participants.
SD= Standard deviation.physiotherapist not involved in the assessments. Partici-
pants exercised alone or in pairs. The resistance training
program followed guidelines from the National Strength
and Conditioning Association [28] and consisted of ten
minutes warm up and 30–40 minutes core strengthening
and single-joint resistance training (using hand-held, free
weights) for strengthening of elbow flexors and exten-
sors, forearm pronators and supinators, and wrist flexors
and extensors. Grip force was trained as well using exer-
cise balls with increasing resistance. The intensity was
set on the basis of 10 repetition maximum strength
tested at baseline [29]. Once the participants were able
to perform three sets of ten repetitions in an exercise,
intensity was built up progressively on an individualized
basis by increasing the weights by 0.25 – 0.5 kg. There
was a one-minute recovery period between all sets and a
two-minute recovery period between different exercises.
Outcome measures
Hand and arm use were evaluated with Melbourne [21]
and with AHA [23]. Melbourne measures unimanual
capacity in tasks that simulate everyday activities. The
children are asked to perform their best in 16 tasks that
are scored according to 37 sub-scores. Percentage scores
(0–100) were calculated and used for analyses [21].
Melbourne has been found to be a reliable and valid in-
strument for measuring quality of upper limb function,
and the smallest detectable difference to measure real
change needs to be at least 12% [30]. A randomized se-
lection of 3–15 items from seven different subjects was
scored by a second therapist. The intra-class correlation
coefficient for the consistency of scorings between thera-
pists was high (ICC= 0.96). AHA is a Rasch-built instru-
ment that measures how children spontaneously use
their involved upper limb in bimanual tasks (i.e. bi-
manual performance) without instructing the child to
perform at their best [23]. The AHA was scored on 22
items with a four-point rating scale (22–88 raw sore).
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(log odds probability units), which were converted to a
0–100 AHA-unit scale [31]. The smallest detectable dif-
ference for AHA is 5 AHA-units [32]. AHA has been
found to be valid and reliable [33] and has been vali-
dated for children up to 12 years. In our study the parti-
cipants were up to 17 years. However, no association
between age and AHA-units was found in the current
study (rs =.202, p=.576), nor in a previous study by our
research group [8] with similar age range. The Baseline
and Post 2 months AHA-unit scores for the participants
were compared to blinded scorings made by an occupa-
tional therapist not involved in the treatment or data
collection. The intra-class correlation between the two
sets of scorings was high (ICC= 0.89).
Neuromuscular body functions were evaluated by test-
ing active range of motion, muscle strength and muscle
tone in spastic muscles. Active range of motion of the
elbow and forearm was measured using a mechanical
goniometer following standard procedures [34]. A sta-
tionary dynamometer BIODEX System 3 Pro (Biodex
Medical Systems, Shirley, NY, USA), found to be reliable
in the lower extremities of children with CP [35,36], was
used to evaluate muscle tone and strength in the elbow
and forearm. Measurements in the elbow were per-
formed with the forearm in neutral position and those in
the forearm with the elbow in 90° flexion. The shoulder
was slightly abducted in all measurements. Muscle tone
was evaluated as resistance to passive movement during
three trials at two velocities, 10°/s and 180°/s, in elbow
extension and forearm supination. Strength was evalu-
ated during three dynamic maximal voluntary contrac-
tions (MVC) at a velocity of 60°/s. One practice trial was
performed first to ensure that the task was performed
correctly. There was a one-minute break between the
trials. The procedure was first carried out on the fore-
arm, then on the elbow. Data analysis was carried out
using Matlab (The Mathworks Inc., Natick, MA, USA),
version 7.6. Prior to further analyses, torque signals were
low-pass filtered with a cut-off frequency of 6 Hz. The
torque recorded during the passive movements at 10°/s
was used to correct the other torque measures for arm
weight. The peak resistance torque during 180°/s in the
trial with the least resistance was used to reflect muscle
tone in the elbow flexors and forearm pronators [35].
The highest peak torque value during the three isokin-
etic contractions was used as strength parameter.
Isometric grip force was measured using GrippitW
(AB Detektor, Göteborg) in the standardized position
recommended by the American Society of Hand Thera-
pists for hand-grip dynamometry [37]. Grippit has been
found to be a reliable instrument for measuring peak
grip strength in children of different age groups [38].
Three maximal trials were performed for each hand, witha two-minute rest period between repetitions. The high-
est peak value during the trials was used for further
analyses.
Statistical analysis
Data were analysed using SPSS, version 18.0 (SPSS Inc.,
Chicago, IL, USA). Non-parametrical analyses were ap-
plied because of the small sample size and deviation
from a normal distribution for several of the variables.
Within-group differences were tested using Wilcoxon
Signed Rank Test, and between-group differences by
means of Mann–Whitney U test for Baseline and in
change scores between Baseline to Post 2 and Post
5 months, respectively. Post 2 months and Post 5 months
were tested separately against Baseline in order to re-
duce the effect of missing data. Significance level was set
at p< .05 and trends at p< .1 are reported. Post-hoc
power calculation suggested that given the sample size,
our study had 80% power to detect a difference in AHA
of three units from Baseline to Post-intervention with a
p-value< .05.
Results
All participants completed the intervention period and
the subsequent Post 2 months assessment. One partici-
pant in group BT dropped out of the Post 5 months
assessment.
At Baseline, the only significant group difference was
higher forearm supination resistance torque in group B
than in group BT (p= .05). Despite differences in gender
distribution between the groups, there were no differ-
ences for any of the strength parameters at baseline.
Results for the hand and arm use measures at Baseline,
Post 2 and Post 5 months are shown in Figure 1. Both
groups had small improvements in hand and arm use.
However, none of the changes were statistically or clinic-
ally significant. For group B, the median change score
from Baseline to Post 2 and Post 5 months was 1 AHA-
unit, while the results for group BT were 1 and 0.5
AHA-unit respectively. The equivalent results from
Melbourne for group B were 1.7 and 0.8% change, and
for group BT 0.8 and 0.4% change. There were no
between-group differences.
Findings for the strength measures at Baseline, Post 2
and Post 5 months are shown in Figure 2. All partici-
pants in group B lost pronation strength (p= .043), and
the majority also experienced small, non-significant
strength losses for all other strength parameters (elbow
flexors: n = 4, elbow extensors: n = 3, supinators: n = 4,
and grip strength: n = 3). In group BT, all participants
increased their grip strength (p= .043). Otherwise there
were no significant changes, although most children
(n = 4) gained strength in elbow flexors, elbow extensors,
and supinators, whereas pronation strength decreased in
Figure 1 Hand and arm use. Box-plots for hand and arm use measured with the Assisting Hand Assessment (AHA) (a) and the Melbourne
Assessment for Unilateral Limb Function (b). Baseline Post 2 months Post 5 months measures’ with Baseline (solid/dark grey) Post 2 months
(striped grey) Post 5 months (dotted/light grey) measures for group B (receiving Botulinum Toxin-A) and group BT (receiving Botulinum Toxin-A
+ 8 weeks of resistance training). Boxes are inter-quartile ranges, the solid horizontal line is the median, whisker bars are the extreme values.









Figure 2 Strength measures. Box-plots for elbow flexion (a) and extension (b), and forearm supination (c) and pronation (d) voluntary
peak torque in Newtonmeter (Nm), and grip force (e) in Newton (N). Baseline Post 2 months Post 5 months measures’ with Baseline (solid/dark
grey) Post 2 months (striped grey) Post 5 months (dotted/light grey) measures for group B (receiving Botulinum Toxin-A) and group BT (receiving
Botulinum Toxin-A+ 8 weeks of resistance training). Boxes are inter-quartile ranges, the solid horizontal line is the median, whisker bars are the
extreme values. Outliers are shown as circles. Significant group differences in treatment effect are indicated.
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nificant or close to significant differences in treatment
effects from Baseline to Post 2 months for all strength
parameters (p’s = .016–.076) except for pronation
strength. From Baseline to Post 5 months, the only sig-
nificant difference in treatment effect between the groups
was in grip strength (p= .050). Otherwise, both groups
were more or less back at their Baseline values.
The muscle tone results, measured as resistance to pas-
sive elbow extension and forearm supination, are shown
in Figure 3. In both groups there was only a small, non-
significant decrease or no change in elbow flexor muscle
tone from Baseline to Post 2 and Post 5 months, with no
between-group differences in treatment effect. Forearm
supination resistance decreased in both groups, but con-
siderably more so in group B (p= .043), resulting in a sig-
nificant difference in treatment effect between the
groups (p= .047).
The results from active forearm supination range at Base-
line, Post 2 and Post 5 months are shown in Figure 4. All
participants in group BT improved their supination range
with a median change of 27.5° (p= .043 from Baseline to
Post 2) and 10° (p= .066 from Baseline to Post 5). For group
B, the results were less consistent. At both post-tests, two
children showed improved range, two had not changed,
and one showed decreased range, giving a median change
in active supination range of 0°. Comparing the two groups,
there was a statistical trend in favour of group BT (p= .093)
for improvements in active supination range from Baseline
to Post 2 months, but no difference between the groups at
5 months. Nearly all participants had close to full active
elbow extension range at Baseline, which did not change
following intervention.
Discussion
This pilot study explored the effects of resistance training
in addition to BoNT-A treatment on hand and arm usea
Figure 3 Muscle tone measures. Box-plots for elbow extension resistance to
Baseline Post 2 months Post 5 months measures’ with Baseline (solid/dark grey) P
group B (receiving Botulinum Toxin-A) and group BT (receiving Botulinum Toxin-
horizontal line is the median, whisker bars are the extreme values. Outliers are shand neuromuscular body functions in a small sample of
children with CP. Our results indicate that the addition
of eight weeks resistance training strengthens non-
injected muscles temporarily, and may possibly reduce
the short-term strength loss that results from BoNT-A
injections in the spastic muscles, without a concomitant
systematic increase in muscle tone. Furthermore, add-
itional resistance training may increase active range of
motion to a larger extent than BoNT-A alone. However,
none of the improvements in neuromuscular body func-
tions further improved hand and arm use at the level of
activity in ICF.
After eight weeks of intensive training, median strength
improvements of 32 to 50% were observed in non-
injected antagonists to the spastic muscles (range elbow
extensors: −14 to 42% and range supinators: −58 to 72%).
This is similar to strength improvements reported previ-
ously in the upper extremities [17,39]. However, our
results demonstrate large variations in the effect of resist-
ance training in this small sample, and some of the parti-
cipants experienced strength losses despite resistance
training. It can therefore be speculated that some chil-
dren with CP might benefit more from resistance train-
ing than others. Based on a review of randomised
controlled trials in the lower limbs, it has recently been
suggested that not all children with CP respond to resist-
ance training to the same extent [40]. Age and severity
might have an effect, and the degree of selective motor
control might also affect the response to training for
some children with unilateral CP [40]. Larger studies are
needed to further investigate this suggestion, using ana-
lytical approaches to determine the sources of variability.
BoNT-A injections alone resulted in a significant de-
crease in muscle tone, but also in a temporary strength
loss in injected spastic muscles, similar to findings
reported by others [14,17,26]. Despite decreased muscle
tone, the ability to generate force in the antagonists tob 
p=.047
rque and forearm supination resistance torque in Newtonmeter (Nm).
ost 2 months (striped grey) Post 5 months (dotted/light grey) measures for
A+8 weeks of resistance training). Boxes are inter-quartile ranges, the solid
own as circles. Significant group differences in treatment effect are indicated.
p=.093
Figure 4 Forearm supination. Box-plot for active forearm
supination range in degrees (deg.). Baseline Post 2 months Post 5
months measures’ with Baseline (solid/dark grey) Post 2 months
(striped grey) Post 5 months (dotted/light grey) measures for group
B (receiving Botulinum Toxin-A) and group BT (receiving Botulinum
Toxin-A+ 8 weeks of resistance training). Boxes are inter-quartile
ranges, the solid horizontal line is the median, whisker bars are the
extreme values. Outliers are shown as circles. Significant group
differences in treatment effect are indicated.
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towards improvement in the participants receiving
BoNT-A treatment only. This indicates that spastic ac-
tivity does not limit strength in the antagonist to the
spastic muscle, at least not at an isokinetic velocity of
60 °/sec. Additional resistance training improved muscle
strength in injected agonists in three children, and it is
therefore possible that strength losses associated with
BoNT-A injections may be counteracted by progressive
resistance training following approved guidelines. Larger
clinical trials are needed to further illuminate these
results, especially since several of the children in our
study were still weakened in the injected muscles despite
resistance training. Consequences of weakening injected
muscles should therefore be considered when using
BoNT-A [17]. In line with current literature [40,41], no
systematic increase in muscle tone was found following
resistance training.
Active supination range improved more in the group
who performed resistance training in the BoNT-A effect
period, and seems to be more effective than BoNT-A
alone, showing a trend approaching significance.
Strengthening of antagonists to spastic muscles in com-
bination with reduction of muscle tone in spastic ago-
nists is a recommended approach [9], but few studies
have addressed the combined effect thoroughly [14].
Most studies have evaluated differences in passive range
of motion following BoNT-A injections and therapy and
found no effect [14]. One recent study found similar
improvements in active elbow extension and wrist
flexion between therapy with and without BoNT-A [17],whereas another study concerned the effect of BoNT-A
in combination with therapy compared to therapy alone,
and found larger improvements in active supination for
therapy alone [16]. However, the latter finding could be
attributed to differences between the groups at baseline.
Active supination range has been found to be a signifi-
cant predictor for activity in the upper extremities [8],
and finding optimal interventions is thus important. It
should therefore be investigated whether or not resist-
ance training alone is more effective in improving active
supination range than resistance training in combination
with BoNT-A, since our results indicate that muscle
weakness constrains active movement to a larger extent
than spasticity.
Grip strength and muscle strength in antagonists to
the spastic muscles (elbow extensors and forearm supi-
nators) improved significantly more in the group who
performed resistance training in combination with
BoNT-A, but did not further improve unimanual or bi-
manual hand and arm use compared to BoNT-A alone.
Similar results were obtained in a recent study by
Rameckers and co-workers [17] showing that increased
muscle strength and accuracy do not necessarily transfer
to improved use of the affected hand in fine motor activ-
ities as measured with Melbourne. There might be sev-
eral reasons for this lack of transfer. To begin with, our
sample size is small and possibly a larger sample would
have revealed other findings. However, none of the parti-
cipants in our study had improvements of 5 AHA-units
or more that is reported to be the smallest detectable
difference to measure real change [32]. A second possi-
bility is that strength gains in our study were not large
enough to engender a meaningful change in hand and
arm use, or that strength gains transfer to other func-
tions than those measured with Melbourne and AHA.
AHA is thought to reflect how a child performs in his or
her usual environment [42], but no test performed in a
standardized environment can fully capture how a child
performs activities in daily life. Future studies should
therefore include this aspect. A final explanation for the
lack of carry-over to functional tasks could be specificity
of training. In particular, for children who are unilat-
erally affected in the upper limbs, it may be due to pro-
blems with motor planning [43] and potential non-use
of the affected hand [44], which could offset gains at the
level of body function. This is in accordance with
Damiano [45] who proposed that treating the impair-
ment alone may be too far removed from the functional
tasks we want to improve. The use of task-related resist-
ance training following single-joint resistance training
may have greater impact on the use of the affected hand
in bimanual activities [10] and would possibly also have
more lasting effects on muscle strength. In our study,
none of the strength improvements were long-lasting. If
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improved muscle strength to improved hand and arm
use, there would be a greater possibility for longer last-
ing effects also on muscle strength. Moreover, it is more
likely that the improved limb functions will be imple-
mented in activities when these activities are explicitly
described as individual goals at the start of therapy.
In addition to the small sample size, the present study
has some other limitations. Assignment to the different
interventions was done by matching the children in pairs
followed by tossing a coin, a method that has been
found to be sensitive to selection bias. Nonetheless, the
procedure resulted in two groups with similar baseline
assessments, except for pronation resistance torque and
gender. The difference in gender between the groups
could have confounded the results if treatment effect
would depend on gender. So far, however, no indications
of such a gender effect are present in the literature, but
caution is warranted. Moreover, the National Strength
and Condition Association [28] states in their updated
position statement paper on youth resistance training
that there is no clear evidence of any major difference in
strength between boys and girls in preadolescents. Thus,
we consider it unlikely that gender is a confounder in
this study. Although difficulty performing daily activities
was not included as a criterion for inclusion, AHA and
Melbourne indicated that all participants had limitations
in the use of the involved hand.
Conclusions
It has previously been found that muscle strength and
active supination range are related to hand and arm use.
It is therefore important to investigate whether treat-
ments targeting these impairments at the level of body
function will have an effect on the level of activity. We
found that resistance training in combination with
BoNT-A did not improve hand and arm use further
compared to BoNT-A alone, even though grip strength
and strength in antagonists to spastic muscles improved
significantly more for the BT group. Specificity of train-
ing and strength gains could be the explanation for this
lack of transfer. In future studies, there is a need for
more insights into whether the use of more task-related
resistance training, alone or in combination with single-
joint resistance training, has greater impact on the use
of the affected hand in bimanual activities, and results in
longer-lasting strength effects than only the general re-
sistance training employed in the current study.
Resistance training improved strength temporarily in
non-injected muscles and may possibly compensate for
the temporary strength loss in injected spastic muscles
due to BoNT-A treatment, without a concomitant in-
crease in muscle tone. However, larger clinical trials are
needed to further investigate whether strength lossesassociated with BoNT-A may be counteracted by resist-
ance training. Furthermore, it should be investigated
whether resistance training in addition to BoNT-A injec-
tions improves active range of motion to a larger degree
than resistance training alone.
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